ARES — Ares Management Corporation

The tape and the sell-side disagree, which is why sentiment reads split rather than clearly bullish or bearish. Analysts remain constructive - consensus is Buy (1 strong buy, 16 buy, 5 hold, 0 sells) with an average 12-month target of $149.33 versus the 2026-09-13 price of $131.64. But the shares have visibly de-rated: -6.07% on the week and -7.52% on the month as of that date, with RSI at 40.83 and price 5.88% below the 20-day SMA. Nothing company-specific explains the drawdown - the Q2 2026 print (released 2026-07-31) beat on revenue ($1.43B vs. ~$1.27B consensus) and EPS, and the Japan Logistics Development Partners V fund closed at its ¥612B hard cap in early September 2026, ~50% larger than the prior vintage. The pressure looks sector-wide: private-credit credit-quality anxiety, rate uncertainty and a general de-rating of high-beta alt managers.

You have to split reported revenue from the fee engine, because they are moving in opposite directions. Revenue ran $671M (Q3'23) -> $1,054M (Q4'23) -> $707M (Q1'24) -> $789M (Q2'24) -> $1,130M (Q3'24) -> $1,259M (Q4'24) -> $1,089M (Q1'25) -> $1,350M (Q2'25) -> $1,658M (Q3'25) -> $1,766M (Q4'25) -> $1,533M (Q1'26) -> $1,429M (Q2'26). YoY growth went +46.7% (Q3'25), +40.3% (Q4'25), +40.8% (Q1'26), then dropped hard to +5.8% in Q2'26. That is performance-fee timing, not deterioration in the recurring business - Q2'26 GAAP revenue still beat the ~$1.27B consensus and FRE grew to $491.1M. GAAP EPS is close to useless as a trend line for this company: it swung from $0.053 (Q1'25) to $0.46 (Q2'25) to $1.15 (Q3'25) to $0.13 (Q4'25) to $0.64 (Q1'26) to $0.49 (Q2'26) on carried-interest compensation and consolidated fund accounting, while after-tax realized income was far steadier at $1.29/share in Q2'26. Free cash flow is equally lumpy and uninformative for an asset manager: -$384M (Q2'26), +$391M (Q1'26), -$499M (Q4'25), +$1.33B (Q3'25). The structural trend underneath is intact - stockholders' equity grew from $1.77B (Q1'24) to $3.97B (Q2'26), AUM reached ~$671B with $410B fee-paying, $170B of dry powder, $114B of AUM not yet paying fees, and a record >$36B of Q2 gross inflows. Verdict: decelerating headline revenue optics masking an accelerating fee annuity - an inflection in optics, not in economics.

The answer depends entirely on which earnings line you use, and the gap is enormous. As of 2026-09-13, at $131.64 on TTM GAAP EPS of $2.812, ARES screens at 57.5x earnings, PEG 2.0, 7.51x book, 6.77x sales versus a 5-year average P/S of 5.52x (so above its own history on sales), with a 3.66% dividend yield. On economic earnings it is a different stock: the FMP FY2027 consensus EPS of $5.859 - roughly consistent with annualizing Q2 2026's $1.29 of after-tax realized income plus growth - implies a forward P/E of just 22.5x. The deterministic overlay labels valuation 'Neutral vs. its own history' (44.1), which is fair given GAAP history anchors are meaningless here. My read: fair to modestly cheap on economic earnings, optically rich on GAAP, and not a bargain on sales or book.

The whole investment case is the GAAP-to-economic earnings bridge. Q2 2026 GAAP net income was $150.6M ($0.49/share) against after-tax realized income of $467.6M ($1.29/share) - a ~2.6x gap created by huge non-cash stock-based/carried-interest compensation and consolidated fund accounting. Screen ARES on 57x GAAP and it looks like a bubble; screen it on 22.5x FY2027 economic EPS and it looks like a reasonably valued compounder in a structural growth market. The 7.5% monthly drawdown as of 2026-09-13 suggests the market is pre-emptively discounting a private-credit accident that has not shown up in the deployment data - Ares closed ~$8.2B of U.S. direct lending commitments in Q2 2026 against $170B of dry powder. The setup: if Q3 2026 (late Oct/early Nov) shows FRE margin progress toward the upper end of the 0-150bps guidance range with stable credit marks and any performance-fee recovery, the GAAP-vs-economic gap should close in the stock's favor. If realized performance income disappoints a second quarter in a row or fund marks wobble, the multiple stays compressed and the 57x GAAP headline keeps scaring off screeners.

As of 2026-09-13, RSI(14) was 40.83 - weak momentum, but nowhere near the 30 oversold line, so there is no capitulation signal. At $131.64 the stock sat 5.88% below its 20-day SMA (~$139.9), 0.95% below its 50-day (~$132.9) and 1.03% below its 200-day (~$133.0). Performance: -6.07% one week, -7.52% one month, -2.42% three months, +29.36% six months. That profile - a large six-month advance now giving back gains into a tightly converged 50/200-day cluster - reads as a range-bound pullback, not a broken trend, but the bias is clearly down. Entry timing implication: the $133 zone (50/200-day) is the line in the sand. A decisive close below it opens the $110-115 area; reclaiming the 20-day near $140 would signal the pullback is finished. The two clean triggers are an RSI flush below 30 or a reclaim of $140 - as of this date, neither has occurred, so there is no urgency to buy.

• Private credit / direct lending tailwind: continued bank retrenchment keeps pushing middle-market borrowers to non-bank lenders - Ares closed ~$8.2B of U.S. direct lending commitments in Q2 2026 and holds $170B of dry powder to deploy.
• Rate path: with a beta of 1.52, ARES is a rate-sensitive financial. A fast cutting cycle lowers funding costs and helps realizations but compresses floating-rate lender spreads, so the pace and direction of Fed policy matters more than the absolute level.
• Private-credit credit quality: the single biggest sector risk. A slowing economy raising mid-market defaults would hit fund marks, performance fees and fundraising simultaneously - the correlation of those three is what makes alt-manager drawdowns sharp.
• Wealth/retail and retirement channel expansion: private markets moving into retail and 401(k) distribution is a multi-year AUM tailwind for Ares's global wealth platform, with regulatory treatment of private assets in retirement accounts as the swing factor.
• High-beta risk appetite: alternative managers trade as leveraged proxies for risk-on sentiment. A broad equity drawdown hits ARES's multiple disproportionately regardless of FRE fundamentals, which is roughly what the last month of price action shows.

• Q3 2026 earnings (expected late October/early November 2026): evidence that fee-related earnings margins are tracking toward the upper end of the 0-150bps improvement guidance, plus the deployment pace of the $170B dry powder.
• Conversion of the $114B of AUM that is not yet paying fees into fee-paying AUM - this converts mechanically into FRE with almost no incremental cost.
• Continued record fundraising: Q2 2026 gross inflows exceeded $36B, and the Japan Logistics Development Partners V fund closed at its ¥612B hard cap in early September 2026, a ~50% step-up over the prior vintage.
• Fed policy path: cuts would help financing costs and exit realizations; the pace of cuts simultaneously determines how much floating-rate spread compression Ares absorbs.
• Performance-fee crystallization: any rebound in transaction activity would revive carried-interest realizations and mechanically narrow the GAAP-to-economic earnings gap that currently makes the stock look expensive on screens.

• Private-credit credit deterioration: rising mid-market defaults would hit fund marks, performance-fee accruals and fundraising at the same time - a triple hit to both earnings and the multiple.
• Performance-fee lumpiness is real: Q2 2026 revenue grew only +5.8% YoY, a stark deceleration from +40%+ in the prior three quarters, showing how fast headline revenue can stall between realizations.
• Balance-sheet leverage: $14.06B of long-term debt against $3.97B of stockholders' equity (D/E 3.75x, LT debt/equity 3.54x). Much is fund-level and non-recourse, but it magnifies rate and refinancing risk and keeps the reported current ratio at 0.83.
• Valuation/multiple risk: 7.51x book and 6.77x sales versus a 5-year average P/S of 5.52x, with beta of 1.52 - a sector de-rating could hold the stock well below intrinsic value for an extended period even if earnings hold up.
• Competitive fee compression: Blackstone, KKR, Apollo and Blue Owl are all chasing the same direct-lending deals, and the $114B of not-yet-fee-paying AUM could be repriced if fundraising competition intensifies.
• GAAP/economic earnings divergence: TTM GAAP EPS of $2.812 against roughly $5.16 of annualized Q2 2026 realized income means any quarter where realized performance income disappoints will look alarming on a GAAP basis and can spook GAAP-focused investors.

High-quality franchise, mediocre near-term setup. The deterministic framework grades ARES 'Weak Fundamentals' because it reads GAAP numbers - and for an alternative asset manager those numbers are structurally depressed by non-cash compensation, so the grade is a misread rather than a signal of deterioration. On the metrics that actually drive value here (FRE of $491.1M/quarter, after-tax realized income of $1.29/share, $671B AUM, $114B of un-fee-paying AUM and $170B of dry powder), ARES is a genuine compounder trading at ~22.5x forward economic earnings as of 2026-09-13. That said, the tape is weak, price is below all three key moving averages, reported revenue growth has decelerated to +5.8% YoY, and the framework's Weak-band/neutral-valuation mapping yields a Bearish lean that I am required to apply. My own numbers put fair value near $152, so I would treat $131.64 as a patient accumulate rather than a chase - wait for either an RSI flush below 30 or a reclaim of the ~$140 20-day SMA. This is analysis, not personalized financial advice.

Forward P/E on economic earnings: I apply a 26x multiple to the FMP FY2027 consensus EPS of $5.859 (which is consistent with annualizing Q2 2026's $1.29 of after-tax realized income plus growth), justified by ~20% fee-related earnings growth, an expanding FRE margin, a 3.66% dividend yield and Ares's premium private-credit franchise versus peers at roughly 20-25x forward economic earnings; 26 x $5.859 = $152.3, rounded to $152. Cross-check: applying 26-27x to an estimated FY2027 FRE of ~$2.2B implies an equity value roughly 15-20% above the current $43.2B market cap, consistent with the earnings-based figure.